Cleveland Biolabs (CBLI) Reports Q1 Loss of $0.06/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress
May 16, 2016 7:30 AM EDTBUFFALO, NY -- (Marketwired) -- 05/16/16 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2016.
Cleveland BioLabs reported a net loss, excluding minority interests, of $(0.7) million for the first quarter of 2016, or $(0.06) per share, compared to a net loss of $(3.7) million, or $(1.14) per share, for the first quarter of 2015.
As of March 31, 2016, the Company had $18.0 million in cash, cash equivalents and short-term investments, which, based on the Company's current operational plan, is expected to fund the Company's operating requirements... More
